6-KThe Wire
Alpha Tau Medical Ltd. files 6-K
Filed Jun 11, 2026 · 1mo ago · Accession 0001213900-26-067573
Plain English
Alpha Tau Medical Ltd. announced it received FDA clearance to complete enrollment in its REGAIN trial for recurrent glioblastoma and add two U.S. clinical sites, with early interim results showing 100% local disease control.
Filing details
- Company
- Alpha Tau Medical Ltd.
- Ticker
- DRTS
- CIK
- 1871321
- Form type
- 6-K
- Filing date
- Jun 11, 2026
- Report date
- Jun 11, 2026
- Document
- ea0294458-6k_alpha.htm
- Size
- 30 KB